Cardiac biomarkers are here to stay

Roche tutorials about Heart Failure, Coronary Artery Disease and Atrial Fibrillation

A broad on-demand assay menu delivers reliable results across a wide range of applications, making test consolidation easy and effective

Worldwide, ischaemic heart disease is the single most common cause of death and its frequency is increasing.

Learn how Roche Diagnostics has helped labs through the most trying times and why Roche is a reliable, strategic and confident choice moving forward.

Roche Digital Pathology expands its commitment to improving patient outcomes and advancing personalized healthcare enabled by open environment innovation.

PCR has become an indispensable tool for many applications in scientific research and clinical investigations due to the continuous development of the ecosystem surrounding the technology.

Effectively manage the growing burden of infectious disease with innovative diagnostic solutions backed by a world-class infrastructure.

Artificial Intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatment.

Roche is starting a collaboration with Ibex Medical Analytics to develop artificial intelligence-based digital pathology applications for improved patient care.

Roche today announced that its cobas® SARS-CoV-2 Test for use on the widely available, high-throughput cobas® 6800/8800 Systems has received Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA) for testing individuals without symptoms or reasons to suspect COVID-19.

The Open Environment allows software developers to easily integrate their image analysis tools for tumour tissue with Roche uPath enterprise software.

Roche press release: Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy.

cobas® 6800/8800 Systems are included as part of the updated World Health Organization (WHO) policy guidelines on nucleic acid amplification tests (NAATs) to detect tuberculosis (TB) and drug-resistant TB. The new guidance expands the number of rapid molecular tests available to national TB programmes in high-burden countries, enabling multi-partner diagnostic approaches that can benefit patients and communities.

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for anti-PD1 immunotherapy.